Dicerna Pharmaceutic (DRNA) 3.41 $DRNA
New Preclinical Data Show Potential of Dicerna GalXC(TM) Subcutaneous Delivery Platform as RNAi Drug Discovery Engine
BusinessWire - Wed Jun 29, 7:00AM CDT
--Initial GalXC Program on Track for First IND Filing in Late 2017
DRNA: 3.41 (-0.07)
Dicerna Appoints Martin Freed, M.D., to Board of Directors
BusinessWire - Wed Jun 15, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of Martin Freed, M.D., former co-founder and chief medical officer of Civitas Therapeutics, Inc., to its board of directors. The appointment will be effective immediately, and increases the size of Dicerna's board of directors to eight members. The board of directors determined Dr. Freed is an independent director.
DRNA: 3.41 (-0.07), CVTS: ()
Dicerna to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference. The presentation will take place on Thursday, June 9, 2016 at 1:30 p.m. ET at the Grand Hyatt in New York City.
DRNA: 3.41 (-0.07)
Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7%
Zacks Equity Research - Zacks Investment Research - Mon May 23, 7:15AM CDT
Dicerna Pharmaceuticals, Inc. (DRNA) shares rose almost 9% in the last trading session.
DRNA: 3.41 (-0.07), ANIP: 55.38 (-1.13)
Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)
BusinessWire - Fri May 13, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first Phase 1 clinical trial of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1). A severe, rare, inherited disorder of the liver, PH1 often results in kidney failure, and there are no approved therapies for the disease.
DRNA: 3.41 (-0.07)
Dicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates
BusinessWire - Wed May 11, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today will present updated preclinical data demonstrating the potency of its proprietary GalNAc-DsiRNA-EX Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) injection, with potential utility against multiple therapeutic targets. The presentation will take place at the 18th Annual TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Conference in Long Beach, Calif.
DRNA: 3.41 (-0.07)
Dicerna Reports First Quarter 2016 Financial and Operational Results
BusinessWire - Mon May 09, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended March 31, 2016.
DRNA: 3.41 (-0.07)
Dicerna to Report First Quarter 2016 Financial Results and Host Conference Call on May 9, 2016
BusinessWire - Mon May 02, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2016 financial results after market close on Monday, May 9, 2016.
DRNA: 3.41 (-0.07)
Dicerna Announces Appointment of John "Jack" Green as Chief Financial Officer
BusinessWire - Mon Apr 18, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of John B. "Jack" Green as chief financial officer (CFO), effective immediately. Mr. Green has served as the Company's interim CFO since January 2016.
DRNA: 3.41 (-0.07)
Alnylam Begins Study for Primary Hyperoxaluria Type 1
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 3:45PM CST
Alnylam Pharmaceuticals (ALNY) announced that it has initiated a phase I/II study on ALN-GO1 for the treatment of primary hyperoxaluria type 1.
DRNA: 3.41 (-0.07), ALNY: 63.46 (+1.28), SNY: 41.42 (+0.57)
Dicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results
BusinessWire - Thu Mar 10, 3:00PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced financial and operational results for the quarter and full year ended December 31, 2015.
DRNA: 3.41 (-0.07)
Dicerna to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10, 2016
BusinessWire - Fri Mar 04, 12:52PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, announced that the Company will release its fourth quarter and full year 2015 financial results after market close on Thursday, March 10, 2016.
DRNA: 3.41 (-0.07)
Dicerna to Present at Two March Conferences
BusinessWire - Wed Mar 02, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following conferences:
DRNA: 3.41 (-0.07)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.30 (-0.18), DRNA: 3.41 (-0.07), INCY: 85.00 (-0.70), LLY: 79.14 (-0.52), STML: 6.98 (-0.01), SNTA: 0.26 (-0.02), ANTH: 3.68 (-0.13), EXEL: 8.15 (unch)
Dicerna to Present at the 2016 Leerink Partners Global Healthcare Conference
BusinessWire - Thu Feb 04, 7:00AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference. The presentation will take place at the Waldorf Astoria in New York City on Thursday, February 11th, 2016 at 11:35 a.m. ET.
DRNA: 3.41 (-0.07)
Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Thu Dec 31, 3:27PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on December 31, 2015, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 115,000 shares of common stock to two new employees, with a grant date of December 31, 2015 (the "Q4 2015 Inducement Grants"
.
DRNA: 3.41 (-0.07)
Alnylam Submits Clinical Trial Application for ALN-GO1 in UK
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 2:50PM CST
Alnylam (ALNY) filed a CTA for ALN-GO1 with the UK Medicines and Healthcare products Regulatory Agency for the treatment of primary hyperoxaluria type 1.
DRNA: 3.41 (-0.07), ALNY: 63.46 (+1.28), ANIK: 52.79 (-0.51), SNY: 41.42 (+0.57)
Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors
BusinessWire - Mon Dec 21, 3:54PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported continued progress in the clinical development of DCR-MYC, Dicerna's investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic designed to silence MYC, an oncogene implicated in multiple tumor types. Dicerna plans to report proof-of-concept data for DCR-MYC in the second half of 2016 based on anticipated results from a Phase 1 clinical trial of DCR-MYC in patients with advanced solid tumors, multiple myeloma, or lymphoma, and a Phase 1b/2 trial in patients with hepatocellular carcinoma (HCC).
DRNA: 3.41 (-0.07)
Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 (PH1) in Healthy Volunteers
BusinessWire - Mon Dec 21, 3:10PM CST
--- Ongoing Observational Study Measures Biomarkers Implicated in the Pathogenesis of PH1 -
DRNA: 3.41 (-0.07)
New Preclinical Data Show Potential of Dicerna GalXC(TM) Subcutaneous Delivery Platform as RNAi Drug Discovery Engine
BusinessWire - Wed Jun 29, 7:00AM CDT
--Initial GalXC Program on Track for First IND Filing in Late 2017
DRNA: 3.41 (-0.07)
Dicerna Appoints Martin Freed, M.D., to Board of Directors
BusinessWire - Wed Jun 15, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of Martin Freed, M.D., former co-founder and chief medical officer of Civitas Therapeutics, Inc., to its board of directors. The appointment will be effective immediately, and increases the size of Dicerna's board of directors to eight members. The board of directors determined Dr. Freed is an independent director.
DRNA: 3.41 (-0.07), CVTS: ()
Dicerna to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference. The presentation will take place on Thursday, June 9, 2016 at 1:30 p.m. ET at the Grand Hyatt in New York City.
DRNA: 3.41 (-0.07)
Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7%
Zacks Equity Research - Zacks Investment Research - Mon May 23, 7:15AM CDT
Dicerna Pharmaceuticals, Inc. (DRNA) shares rose almost 9% in the last trading session.
DRNA: 3.41 (-0.07), ANIP: 55.38 (-1.13)
Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)
BusinessWire - Fri May 13, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first Phase 1 clinical trial of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1). A severe, rare, inherited disorder of the liver, PH1 often results in kidney failure, and there are no approved therapies for the disease. DRNA: 3.41 (-0.07)
Dicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates
BusinessWire - Wed May 11, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today will present updated preclinical data demonstrating the potency of its proprietary GalNAc-DsiRNA-EX Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) injection, with potential utility against multiple therapeutic targets. The presentation will take place at the 18th Annual TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Conference in Long Beach, Calif. DRNA: 3.41 (-0.07)
Dicerna Reports First Quarter 2016 Financial and Operational Results
BusinessWire - Mon May 09, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq
RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended March 31, 2016. DRNA: 3.41 (-0.07)
Dicerna to Report First Quarter 2016 Financial Results and Host Conference Call on May 9, 2016
BusinessWire - Mon May 02, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2016 financial results after market close on Monday, May 9, 2016.
DRNA: 3.41 (-0.07)
Dicerna Announces Appointment of John "Jack" Green as Chief Financial Officer
BusinessWire - Mon Apr 18, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of John B. "Jack" Green as chief financial officer (CFO), effective immediately. Mr. Green has served as the Company's interim CFO since January 2016. DRNA: 3.41 (-0.07)
Alnylam Begins Study for Primary Hyperoxaluria Type 1
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 3:45PM CST
Alnylam Pharmaceuticals (ALNY) announced that it has initiated a phase I/II study on ALN-GO1 for the treatment of primary hyperoxaluria type 1.
DRNA: 3.41 (-0.07), ALNY: 63.46 (+1.28), SNY: 41.42 (+0.57)
Dicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results
BusinessWire - Thu Mar 10, 3:00PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced financial and operational results for the quarter and full year ended December 31, 2015.
DRNA: 3.41 (-0.07)
Dicerna to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10, 2016
BusinessWire - Fri Mar 04, 12:52PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, announced that the Company will release its fourth quarter and full year 2015 financial results after market close on Thursday, March 10, 2016.
DRNA: 3.41 (-0.07)
Dicerna to Present at Two March Conferences
BusinessWire - Wed Mar 02, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following conferences:
DRNA: 3.41 (-0.07)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.30 (-0.18), DRNA: 3.41 (-0.07), INCY: 85.00 (-0.70), LLY: 79.14 (-0.52), STML: 6.98 (-0.01), SNTA: 0.26 (-0.02), ANTH: 3.68 (-0.13), EXEL: 8.15 (unch)
Dicerna to Present at the 2016 Leerink Partners Global Healthcare Conference
BusinessWire - Thu Feb 04, 7:00AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference. The presentation will take place at the Waldorf Astoria in New York City on Thursday, February 11th, 2016 at 11:35 a.m. ET.
DRNA: 3.41 (-0.07)
Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Thu Dec 31, 3:27PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on December 31, 2015, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 115,000 shares of common stock to two new employees, with a grant date of December 31, 2015 (the "Q4 2015 Inducement Grants"
. DRNA: 3.41 (-0.07)
Alnylam Submits Clinical Trial Application for ALN-GO1 in UK
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 2:50PM CST
Alnylam (ALNY) filed a CTA for ALN-GO1 with the UK Medicines and Healthcare products Regulatory Agency for the treatment of primary hyperoxaluria type 1.
DRNA: 3.41 (-0.07), ALNY: 63.46 (+1.28), ANIK: 52.79 (-0.51), SNY: 41.42 (+0.57)
Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors
BusinessWire - Mon Dec 21, 3:54PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ
RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported continued progress in the clinical development of DCR-MYC, Dicerna's investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic designed to silence MYC, an oncogene implicated in multiple tumor types. Dicerna plans to report proof-of-concept data for DCR-MYC in the second half of 2016 based on anticipated results from a Phase 1 clinical trial of DCR-MYC in patients with advanced solid tumors, multiple myeloma, or lymphoma, and a Phase 1b/2 trial in patients with hepatocellular carcinoma (HCC). DRNA: 3.41 (-0.07)
Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 (PH1) in Healthy Volunteers
BusinessWire - Mon Dec 21, 3:10PM CST
--- Ongoing Observational Study Measures Biomarkers Implicated in the Pathogenesis of PH1 -
DRNA: 3.41 (-0.07)
